Direct Optic Nerve Sheath (DONS) Application of Schwann Cells Prolongs Retinal Ganglion Cell Survival in Vivo

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2014 Oct 17

PMID 25321467

Citations 18

Authors

L Guo

B Davis

S Nizari

E M Normando

H Shi

J Galvao

L Turner

J Shi

M Clements

S Parrinello

M F Cordeiro

Affiliations

Soon will be listed here.

Abstract

Cell-based therapies are increasingly recognized as a potential strategy to treat retinal neurodegenerative disease. Their administration, however, is normally indirect and complex, often with an inability to assess in real time their effects on cell death and their migration/integration into the host retina. In the present study, using a partial optic nerve transection (pONT) rat model, we describe a new method of Schwann cell (SC) delivery (direct application to injured optic nerve sheath, SC/DONS), which was compared with intravitreal SC delivery (SC/IVT). Both SC/DONS and SC/IVT were able to be assessed in vivo using imaging to visualize retinal ganglion cell (RGC) apoptosis and SC retinal integration. RGC death in the pONT model was best fitted to the one-phase exponential decay model. Although both SC/DONS and SC/IVT altered the temporal course of RGC degeneration in pONT, SC/DONS resulted in delayed but long-lasting effects on RGC protection, compared with SC/IVT treatment. In addition, their effects on primary and secondary degeneration, and axonal regeneration, were also investigated, by histology, whole retinal counting, and modelling of RGC loss. SC/DONS was found to significantly reduce RGC apoptosis in vivo and significantly increase RGC survival by targeting secondary rather than primary degeneration. Both SC/DONS and SC/IVT were found to promote RGC axonal regrowth after optic nerve injury, with evidence of GAP-43 expression in RGC somas and axons. SC/DONS may have the potential in the treatment of optic neuropathies, such as glaucoma. We show that SC transplantation can be monitored in real time and that the protective effects of SCs are associated with targeting secondary degeneration, with implications for translating cell-based therapies to the clinic.

Citing Articles

Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation.

Sharif N Curr Res Neurobiol. 2023; 3:100037.

PMID: 36685768 PMC: 9846481. DOI: 10.1016/j.crneur.2022.100037.

Tools and Biomarkers for the Study of Retinal Ganglion Cell Degeneration.

Corral-Domenge C, de la Villa P, Mansilla A, Germain F Int J Mol Sci. 2022; 23(8).

PMID: 35457104 PMC: 9025234. DOI: 10.3390/ijms23084287.

Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.

Sharif N Front Pharmacol. 2021; 12:729249.

PMID: 34603044 PMC: 8484316. DOI: 10.3389/fphar.2021.729249.

Dynamic changes in cell size and corresponding cell fate after optic nerve injury.

Davis B, Guo L, Ravindran N, Shamsher E, Baekelandt V, Mitchell H Sci Rep. 2020; 10(1):21683.

PMID: 33303775 PMC: 7730151. DOI: 10.1038/s41598-020-77760-1.

Topical recombinant human Nerve growth factor (rh-NGF) is neuroprotective to retinal ganglion cells by targeting secondary degeneration.

Guo L, Davis B, Ravindran N, Galvao J, Kapoor N, Haamedi N Sci Rep. 2020; 10(1):3375.

PMID: 32099056 PMC: 7042238. DOI: 10.1038/s41598-020-60427-2.

References

Geddes D, Cargill 2nd R, LaPlaca M . Mechanical stretch to neurons results in a strain rate and magnitude-dependent increase in plasma membrane permeability. J Neurotrauma. 2003; 20(10):1039-49. DOI: 10.1089/089771503770195885. View

Campbell G, Kitching J, Anderson P, Lieberman A . Different effects of astrocytes and Schwann cells on regenerating retinal axons. Neuroreport. 2003; 14(16):2085-8. DOI: 10.1097/00001756-200311140-00015. View

Cordeiro M, Guo L, Luong V, Harding G, Wang W, Jones H . Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci U S A. 2004; 101(36):13352-6. PMC: 516570. DOI: 10.1073/pnas.0405479101. View

Isenmann S, Kretz A, Cellerino A . Molecular determinants of retinal ganglion cell development, survival, and regeneration. Prog Retin Eye Res. 2003; 22(4):483-543. DOI: 10.1016/s1350-9462(03)00027-2. View

Savigni D, Doig R, Szymanski C, Bartlett C, Lozic I, Smith N . Three Ca2+ channel inhibitors in combination limit chronic secondary degeneration following neurotrauma. Neuropharmacology. 2013; 75:380-90. DOI: 10.1016/j.neuropharm.2013.07.034. View

Levkovitch-Verbin H, Dardik R, Vander S, Melamed S . Mechanism of retinal ganglion cells death in secondary degeneration of the optic nerve. Exp Eye Res. 2009; 91(2):127-34. DOI: 10.1016/j.exer.2009.11.014. View

Chew S, Johnson C, Green C, Danesh-Meyer H . Response of retinal Connexin43 to optic nerve injury. Invest Ophthalmol Vis Sci. 2011; 52(6):3620-9. DOI: 10.1167/iovs.10-6318. View

Bhatheja K, Field J . Schwann cells: origins and role in axonal maintenance and regeneration. Int J Biochem Cell Biol. 2006; 38(12):1995-9. DOI: 10.1016/j.biocel.2006.05.007. View

Levkovitch-Verbin H, Quigley H, DAnna S, Kerrigan D, Pease M . Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci. 2001; 42(5):975-82. View

10.

Kwong J, Quan A, Kyung H, Piri N, Caprioli J . Quantitative analysis of retinal ganglion cell survival with Rbpms immunolabeling in animal models of optic neuropathies. Invest Ophthalmol Vis Sci. 2011; 52(13):9694-702. PMC: 3341125. DOI: 10.1167/iovs.11-7869. View

11.

Cummins N, Bartlett C, Archer M, Bartlett E, Hemmi J, Harvey A . Changes to mitochondrial ultrastructure in optic nerve vulnerable to secondary degeneration in vivo are limited by irradiation at 670 nm. BMC Neurosci. 2013; 14:98. PMC: 3844486. DOI: 10.1186/1471-2202-14-98. View

12.

Clarke G, Collins R, Leavitt B, ANDREWS D, Hayden M, Lumsden C . A one-hit model of cell death in inherited neuronal degenerations. Nature. 2000; 406(6792):195-9. DOI: 10.1038/35018098. View

13.

Ben Borgens R, Liu-Snyder P . Understanding secondary injury. Q Rev Biol. 2012; 87(2):89-127. DOI: 10.1086/665457. View

14.

Magharious M, DOnofrio P, Koeberle P . Optic nerve transection: a model of adult neuron apoptosis in the central nervous system. J Vis Exp. 2011; (51). PMC: 3197096. DOI: 10.3791/2241. View

15.

Doig R, Bartlett C, Maghzal G, Lam M, Archer M, Stocker R . Reactive species and oxidative stress in optic nerve vulnerable to secondary degeneration. Exp Neurol. 2014; 261:136-46. DOI: 10.1016/j.expneurol.2014.06.007. View

16.

Quigley H . Glaucoma. Lancet. 2011; 377(9774):1367-77. DOI: 10.1016/S0140-6736(10)61423-7. View

17.

Singhal S, Bhatia B, Jayaram H, Becker S, Jones M, Cottrill P . Human Müller glia with stem cell characteristics differentiate into retinal ganglion cell (RGC) precursors in vitro and partially restore RGC function in vivo following transplantation. Stem Cells Transl Med. 2012; 1(3):188-99. PMC: 3659849. DOI: 10.5966/sctm.2011-0005. View

18.

Li S, Hu B, Tay D, So K, Yip H . Intravitreal transplants of Schwann cells and fibroblasts promote the survival of axotomized retinal ganglion cells in rats. Brain Res. 2004; 1029(1):56-64. DOI: 10.1016/j.brainres.2004.09.038. View

19.

Hu Y, Arulpragasam A, Plant G, Hendriks W, Cui Q, Harvey A . The importance of transgene and cell type on the regeneration of adult retinal ganglion cell axons within reconstituted bridging grafts. Exp Neurol. 2007; 207(2):314-28. DOI: 10.1016/j.expneurol.2007.07.001. View

20.

Fitzgerald M, Bartlett C, Harvey A, Dunlop S . Early events of secondary degeneration after partial optic nerve transection: an immunohistochemical study. J Neurotrauma. 2009; 27(2):439-52. DOI: 10.1089/neu.2009.1112. View